Abstract: In this study,the ICR mice were divided into normal control group,high-fat model group and soybean peptide dose group. The dose of gavage was 200,400 mg/kg and 800 mg/kg respectively. The effects of soybean active peptide on obesity and dyslipidemia induced by high-fat were analyzed by analyzing the changes of body weight and blood lipid. The results showed that the body weight,Lee’s index,food intake,liver and adipose tissue weight of obese mice in the high-fat model group decreased significantly(P<0.05)after high dose of soybean active peptide was administered to the stomach. The contents of total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C)were significantly decreased(P<0.05),while the contents of high-density lipoprotein cholesterol(HDL-C)were significantly increased(P<0.05). The content of TC in liver decreased significantly(P<0.05),while that in feces increased significantly(P<0.05). Compared with the normal control group,there was no significant difference in body weight,Lee’s index,food intake,liver weight,fat coefficient,TC,TG,LDL-C and HDL-C in the high dose group(P>0.05),while the TC content in feces increased significantly(P<0.05). The results of liver tissue section showed that soybean active peptide could reduce the degree of fatty degeneration of liver,and the effect of high dose group was the most obvious. Therefore,the soybean polypeptide has a good weight-loss effect.